Enhanced Fc and complement activity of Fc-modified avelumab boosts anti-tumor activity but promotes NK cell fratricide
{{output}}
Objectives: The anti-PD-L1 antibody avelumab has demonstrated efficacy across multiple cancer types. Avelumab primarily blocks the PD-1/L1 immune checkpoint, while inducing antibody-dependent cellular cytotoxicity (ADCC) from CD1... ...
